Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor

Area of Science:

• Molecular Biology
• Cell Biology
• Developmental Biology

Background:

• Angiogenesis is crucial for physiological and pathological processes, including tumor development.
• Drm/gremlin, a bone morphogenic protein (BMP) antagonist, is known to influence growth and differentiation.
• Its role in angiogenesis has not been previously established.

Purpose of the Study:

• To identify Drm/gremlin as a novel proangiogenic factor.
• To investigate the direct interaction of Drm/gremlin with endothelial cells.
• To explore the therapeutic potential of Drm/gremlin in angiogenesis-related diseases.

Main Methods:

• Purification of Drm/gremlin from conditioned medium of transformed endothelial cells.
• In vitro assays measuring endothelial cell migration, invasion, and binding.
• In vivo neovascularization assay using chick embryo chorioallantoic membrane.
• Analysis of Drm/gremlin expression in human tumor xenografts and lung tumors.

Main Results:

• Drm/gremlin was purified and identified as an endothelial cell-expressed factor.
• Recombinant Drm/gremlin stimulated endothelial cell migration, invasion, and binding.
• Drm/gremlin induced neovascularization in vivo and triggered intracellular signaling.
• Drm/gremlin is upregulated in tumor vasculature compared to non-neoplastic tissue.

Conclusions:

• Drm/gremlin is a novel proangiogenic factor that directly interacts with endothelial cells.
• Drm/gremlin modulates angiogenesis through direct endothelial cell interaction.
• Drm/gremlin expression in tumor vasculature suggests a role in tumor angiogenesis.